Gan & Lee Pharmaceuticals Co Ltd
603087
Company Profile
Business description
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Contact
No. 8, 1st Nanfeng West Road
Zhenxian Town
Tongzhou District
Beijing101102
CHNT: +86 1080593699
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
5,245
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.60 | 15.10 | 0.17% |
| CAC 40 | 7,930.22 | 34.28 | 0.43% |
| DAX 40 | 23,967.60 | 86.88 | 0.36% |
| Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
| FTSE 100 | 9,411.44 | 61.01 | 0.65% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,660.01 | 68.86 | 0.30% |
| Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,688.46 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |